Related references
Note: Only part of the references are listed.B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
T-bet promotes potent antitumor activity of CD4+ CAR T cells
Albert T. Gacerez et al.
CANCER GENE THERAPY (2018)
Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles
David F. Tucker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall et al.
JCI INSIGHT (2018)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance
Giovanni Carulli et al.
ACTA HAEMATOLOGICA (2016)
Utility of CD54, CD229, and CD319 for the Identification of Plasma Cells in Patients with Clonal Plasma Cell Diseases
Fanny Pojero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Multiple Myeloma: New Surface Antigens for the Characterization of Plasma Cells in the Era of Novel Agents
Vittorio Emanuele Muccio et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Maksim Mamonkin et al.
BLOOD (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Overcoming nutrient limitations for cell-based production of influenza vaccine
Sara Yousef et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher et al.
CLINICAL CANCER RESEARCH (2012)
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Ole Audun Werner Haabeth et al.
NATURE COMMUNICATIONS (2011)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Application of phage display to high throughput antibody generation and characterization
Darren J. Schofield et al.
GENOME BIOLOGY (2007)
A simple vector system to improve performance and utilisation of recombinant antibodies
Cecile D. Martin et al.
BMC BIOTECHNOLOGY (2006)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
DL Porter et al.
BLOOD (2006)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity
RA Kemp et al.
JOURNAL OF IMMUNOLOGY (2001)
Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9
MA de la Fuente et al.
BLOOD (2001)
Share Paper
